ALK-Abelló A/S

ALK B

DK0061802139

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:56:31 2024-05-14 am EDT			5-day change	1st Jan Change
154.3 ^DKK	+0.65%		+0.85%	+52.96%

May. 03	Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024
May. 02	ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

ALK-Abelló A/S Approves the New Election of Anders Hedegaard as Chairman of the Board of Directors

March 11, 2020 at 12:26 pm EDT

ALK-Abelló A/S announced at its Annual General Meeting held on 11 March 2020, approved the new election of Anders Hedegaard as Chairman of the Board of Directors.

Latest news about ALK-Abelló A/S

Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024	May. 03
ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
ALK-Abelló A/S Updates Revenue Guidance for the Year 2024	May. 02	CI
ALK-Abelló A/S Provides Earnings Guidance for the Year 2024	May. 02	CI
Transcript : ALK-Abelló A/S - Shareholder/Analyst Call	Mar. 14
New entries in MarketScreener's Europe portfolio	Mar. 04
Transcript : ALK-Abelló A/S, Q4 2023 Earnings Call, Feb 08, 2024	Feb. 08
ALK-Abelló A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024	Feb. 08	CI
ALK-Abelló’s Carbon Reduction Targets Gets Validation from Science-Based Targets Initiative	Feb. 05	MT
Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review	Jan. 25	CI
ALK-Abelló’s Peanut Allergy Treatment Shows Safety, Tolerability in First Part of Early-stage Trial	Jan. 18	MT
ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet	Jan. 18	CI
ALK-Abelló Closes Purchase of US Skin Antigen Test Maker AllerQuest	Jan. 04	MT
ALK-Abelló A/S (CPSE:ALK B) acquired Business Assets of AllerQuest.	Jan. 03	CI
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	Dec. 12	CI
Transcript : ALK-Abelló A/S, Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Alk-Abelló A/S Provides Earnings Guidance for the Year 2023	Nov. 15	CI
ALK-Abelló A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet	23-10-11	CI
Transcript : ALK-Abelló A/S, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
ALK-Abelló A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023	23-08-24	CI
Correction: ALK-Abelló President, CEO to Step Down at 2023-End; Successor Named	23-06-19	MT
ALK-Abelló President/CEO to Step Down at 2023-End; Successor Named	23-06-19	MT

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Sector

Pharmaceuticals

Calendar

2024-06-03 - Capital Markets Day

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ALK-Abelló A/S : No allergy on the horizon

March 12, 2024 at 10:20 am EDT

More Strategies

Ratings for ALK-Abelló A/S

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

153.3 DKK

Average target price

155 DKK

Spread / Average Target

+1.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALK-ABELLÓ A/S	+52.96%	4.9B
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+31.74%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.51%	240B
NOVARTIS AG	+9.45%	209B
ROCHE HOLDING AG	-8.75%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals

ALK-Abelló A/S

Equities

ALK B

DK0061802139

Pharmaceuticals

ALK-Abelló A/S Approves the New Election of Anders Hedegaard as Chairman of the Board of Directors

Latest news about ALK-Abelló A/S

Chart ALK-Abelló A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for ALK-Abelló A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals